Previous 10 | Next 10 |
MORRISVILLE, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has extended its strategic partnership with Medable, the industry-leading technology platform for patient-centered cl...
Summary The rising cost of capital, weakening growth trends, and issues with a key customer segment in its clinical business have led to disappointing -66.84% YTD returns. The global contract research organization services market is estimated to reach $135.26 billion by 2030. Syneos Hea...
MORRISVILLE, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 2023 Health Trends: Personally, Purposely Building What's Next . From Artificial Intelligence (AI) and machine le...
MORRISVILLE, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to participate in a fireside chat at the 2022 Evercore IS...
Summary Little has changed for Syneos Health following its latest set of numbers. An increasing cost of capital and weakening growth trends have clamped investor sentiment for SYNH in FY22. Market data also suggests there's a lack of institutional support, whilst investors hav...
The shares of contract research organization Syneos Health ( NASDAQ: SYNH ) added ~17% on Monday, reversing a sharp selloff that followed the company's Q3 2022 results on Friday. Citing lower-than-expected net awards, revenue, and margins as reasons for the underperforma...
Syneos Health, Inc. (SYNH) Q3 2022 Earnings Conference Call November 4, 2022 8:00 AM ET Company Participants Ronnie Speight - Senior Vice President, Investor Relations Michelle Keefe - Chief Executive Officer Jason Meggs - Chief Financial Officer Michael Broo...
Syneos Health, Inc. ( NASDAQ: SYNH ) lost ~23% pre-market Friday after the contract research organization missed Street forecasts with its Q3 2022 results and lowered the outlook to a level below the consensus estimates. “We are disappointed in our third quarter r...
The following slide deck was published by Syneos Health, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Syneos Health, Inc. 2022 Q3 - Results - Earnings Call Presentation
Syneos Health press release ( NASDAQ: SYNH ): Q3 Non-GAAP EPS of $1.23 misses by $0.09 . Revenue of $1.34B (-0.7% Y/Y) misses by $40M . Adjusted EBITDA of $210.0M increased 3.7% Y/Y. The company’s Net Leverage Ratio was 3.2x based on trailing twelve ...
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...